4428-98-2

Basic information

• Product Name: N-Cyanomethanimidic acid ethyl ester
• Synonyms: N-Cyanomethanimidic acid ethyl ester;(Ethoxymethylene)cyanamide;Ethyl N-cyanoformimidate;Ethyl N-cyanomethanimidate;(E)-(ethyl N-cyanoMethenecarboxiMidate);(Z)-Ethyl N-cyanoformimidate;ethyl cyanoimidoformate;METHANIMIDIC ACID, N-CYANO-, ETHYL ESTER
• CAS NO: 4428-98-2
• Molecular Formula: C₄H₆N₂O
• Molecular Weight: 98
• Mol File: 4428-98-2.mol

Chemical Properties

• Boiling Point: 116℃
• Flash Point: 24℃
• Appearance: /
• Density: 0.94
• CAS DataBase Reference: N-Cyanomethanimidic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-Cyanomethanimidic acid ethyl ester(4428-98-2)
• EPA Substance Registry System: N-Cyanomethanimidic acid ethyl ester(4428-98-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 4428-98-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Cyanomethanimidic acid ethyl ester is used as a reagent for the preparation of C-nucleosides, which are considered potential agents against Hepatitis C Virus (HCV). Its role in the synthesis of these therapeutic agents is crucial, as it enables the development of effective treatments for this viral infection.

Upstream product

• 420-04-2 CYANAMID 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 105364-26-9 C₇H₆N₄ 
• 1489-04-9 5-azaadenine 
• 132901-76-9 C₁₀H₉ClN₆ 
• 132901-77-0 anisaldehyde amino(N-cyanoiminomethyl)aminomethylenehydrazone 
• 83184-33-2 N-cyano-N'-(3-1H-imidazol-4-ylphenyl)formamidine 
• 132707-61-0 2-Phenyl-1,2-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ylamine 
• 132685-79-1 2-Methyl-2-phenyl-1,2-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ylamine 
• 132707-62-1 2-(2-Bromo-phenyl)-1,2-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ylamine 
• 132901-80-5 C₁₁H₁₁ClN₆ 
• 132685-80-4 2-(4-Chloro-phenyl)-2-methyl-1,2-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-ylamine 
• 132901-81-6 C₁₂H₁₄N₆O 
• 132685-81-5 5-amino-2-(p-methoxyphenyl)-2-methyl-2H-<1,2,4>triazolo<1,5-a><1,3,5>triazine 
• 132901-83-8 C₁₃H₁₆N₆ 
• 28610-03-9 5-amino-2-phenyl-<1,2,4>triazolo<1,5-a><1,3,5>triazine 

Relevant articles and documents

Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents

The kinetoplastid parasites Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are the causative agents of neglected tropical diseases with a serious burden in several parts of the world. These parasites are incapable of synthesizing purines de nov

Synthetic methods for preparing ionic liquids containing hypophosphite and carbon-extended dicyanamide anions

Chemical methodology: New synthetic methods to prepare ionic liquids containing the hypophosphite (HP) and carbon-extended dicyanamide (DCA) anions (vinylogous DCA and N,N′-dicyanoformamide (DCF)) have been developed (see scheme). The performance of these materials as hypergolic ionic liquids has also been evaluated. Copyright

5-FLUORO PYRIMIDINE DERIVATIVES

This present disclosure is related to the field of 5-fluoro pyrimidines and their derivatives and to the use of these compounds as fungicides.

Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction

The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure derivatives, and formulations thereof, and processes for preparing the same. Further disclosed are methods of treating a phys

SUBSTITUTED BENZIMIDAZOLES AND THEIR USE FOR INDUCING APOPTOSIS

The invention relates to compounds of formula (I), wherein R represents aryl or heteroaryl, X is a bond, a carbonyl group, a derivative of a carbonyl group, an ethylene group or an ethylenecarbonyl group, R1 is optionally substituted amino or hydroxy, and the substituents R2 to R6 have the meanings given in the specification, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to intermediates, to the use of a compounds of formula (I) as a medicament and for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same.

METHOD FOR CARRYING OUT THE CATALYST-FREE PRODUCTION OF O-ALKYL-N-CYANOFORMIMIDATES

The invention relates to a method for producing O-alkyl-N-cyanoformimidates, during which the reaction of cyanamide with orthoformic acid alkyl esters ensues with a molar ratio of 1: 0.8 to 10.0 without the addition of a catalyst, at pressures ranging from 0.1 to 10 bar, and at a temperature ranging from 40 to 180 °C. It is advantageous to remove alkanol formed during the reaction from the reaction mixture and to work, by and large, without using solvents. The product is obtained in very good yields and with utmost purity in a technically simple manner under environmentally friendly conditions.

Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof

A process for preparing xanthine phosphodiesterase V inhibitors, and compounds utilized in said process. The process includes a five-step methodology for efficient synthesis of Compound 5 without intermediate purifications or separations, a dihalogenation step to synthesize Compound 7, and a coupling reaction to produce Compound 9.

1-Substituted xanthines

A convenient general procedure for the preparation of 1-alkyl-, 1-aryl-, and 1-aminoxanthines from an easily prepared imidazole precursor is described.